Marché mondial du diagnostic moléculaire – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché du diagnostic moléculaire

L'incidence croissante des maladies infectieuses et du cancer à l'échelle mondiale a accru l'adoption des diagnostics moléculaires. Les principaux acteurs du marché se concentrent désormais principalement sur les avancées technologiques en matière de diagnostic moléculaire. En outre, on a pu constater pendant la COVID-19 que l'industrie du diagnostic a connu une forte croissance, avec une course au développement de nouveaux kits de diagnostic rapides pour la détection du coronavirus. En 2021, une augmentation de 59 % du chiffre d'affaires a été signalée par Thermo Fisher Scientific en raison de la division diagnostic qui a enregistré une croissance de 150 %.

Français Data Bridge Market Research analyse que le marché du diagnostic moléculaire, qui était de 20,1 milliards USD en 2022, atteindrait 54,76 milliards USD d'ici 2030 et devrait connaître un TCAC de 13,3 % au cours de la période de prévision de 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du diagnostic moléculaire

Market Definition

Molecular diagnosis can detect the diseases such as hereditary diseases, infectious diseases, neurological diseases, cardiovascular diseases, and others by examining molecules such as DNA, RNA, and protein in a tissue or a fluid. Numerous methods, such as mass spectrometry, PCR, next-generation sequencing, in situ hybridization, molecular imaging, and others, are used to diagnose several diseases. Molecular diagnostics uses strong technologies such as DNA sequence analysis, gene expression profiling, and biomarker identification to identify disorders correctly.

Global Molecular Diagnostics Market Dynamics

Drivers

• Increasing Elderly Population

The increasing geriatric population worldwide is surging the risk of getting several diseases, such as cardiovascular diseases, cancer, obesity, neurological disorders, and diabetes. As per the UN report, in 2020, there were around 727 million people aged 65 years and above worldwide. In addition to this, the number of individuals aged 80 years and above is anticipated to double by 2050. The geriatric population is more likely to suffer from multiple diseases due to multimorbidity, decreased immune function, and aging-related physiological changes. Thus, this factor boosts market growth.

• High Usage of PCR

PCR is highly used in CROs, research institutes, and hospitals, enhancing the market growth rate. The growing use of high-throughput PCR technology to detect infectious and genetic diseases is anticipated to surge market growth. For instance, Seegene announced the launch of its upcoming Allplex SARS-CoV-2 Fast PCR Assay in 2022. The test has a turnaround time of 60 minutes and thus is appropriate for mass testing. Thus, this factor boosts market growth.

Opportunities

• Increasing Demand for Molecular Diagnostics in Point-of-Care Setting

In recent years, molecular diagnostic platforms have been widely used in PoC settings. Numerous companies are designing molecular diagnostic platforms and assays for POC or near-patient testing. In addition to this, the increasing development of new assays that provide quick PoC results is estimated to enhance market growth. For instance, Abbott launched a molecular point of care test, the ID NOW COVID-19 test, to diagnose COVID-19 in less than 5 minutes in 2020. Thus, this factor boosts market growth.  

• Increasing Prevalence of HIV

The increasing incidence of infectious diseases is anticipated to boost market growth over the forecast period. The growing occurrence of STIs, such as HIV and HPV, is anticipated to enhance the market growth as all these diseases demand a high rate of molecular tests. As per the WHO records, the prevalence of HIV was approximately 37.7 million and 1.5 million, respectively, in 2020. Additionally, people who have HIV are highly vulnerable to other infections, such as tuberculosis. All these infectious diseases demand multiple molecular tests, which will further help in faster treatment processes. Thus, this factor boosts market growth.

Restraints/Challenges

• Increasing Regulatory Approvals

The regulatory framework for approval is the main limiting factor in the market's growth. Many times, inaccurate results may be attained because of some fault in the diagnostic kits or an untrained person performing the test. Thus, strict regulation has been related to the approval process. Thus, this factor is restricting the market growth.

This molecular diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the molecular diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Roche Diagnostics India launched the Cobas 8800 and the Cobas 6800 at the National Institute of Cholera and Enteric Diseases, Kolkata,  to help the SARS CoV-2 diagnostic testing. The Roche Cobas 6800/8800 systems deliver test findings in a time of three and a half hours and allow greater operational efficiency, flexibility, and the quickest time-to-results.
• In 2021, Roche completed the acquisition of TIB Molbiol Group. TIB Molbiol Group has about 45 CE-IVD-approved assays for diagnosing inherited genetic testing, infectious diseases, transplant medicine, and hematology testing.

Global Molecular Diagnostics Market Scope

The molecular diagnostics market is segmented on the basis of products, technology, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Reagents and Kits
• Instruments
• Services and Software

 Technology

• Mass Spectrometry (MS)
• Capillary Electrophoresis
• Next Generation Sequencing (NGS)
• Chips and Microarray
• Polymerase Chain Reaction (PCR)-Based Methods
• Cytogenetics
• In Situ Hybridization (ISH or FISH)
• Molecular Imaging
• Others

Application

• Oncology
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
•  Other Cancers
• Pharmacogenomics
• Microbiology
• Prenatal Tests
• Tissue Typing
• Blood Screening
• Cardiovascular Diseases
• Neurological Diseases
• Infectious Diseases
• COVID-19
• Hepatitis
• HIV
• CT/NG
• HAI
• HPV
• Tuberculosis
• Influenza
• Others
• Others

End User

• Hospital
• Clinical Laboratories
• Academics

Molecular Diagnostics Market Regional Analysis/Insights

The molecular diagnostics market is analyzed and market size insights and trends are provided by products, technology, application and end user as referenced above.

The countries covered in the molecular diagnostics market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the molecular diagnostics market because of the increased per capita healthcare expenditure and increasing demand for better healthcare facilities. Also, a high standard of living and consumer awareness about early diagnosis, and the well-established healthcare system are major factors for the market growth. 

Asia-Pacific is expected to witness significant growth due to the high elderly population, growing incidence of cancer and varied infectious disease in countries such as China and India, and the advanced healthcare infrastructure within the region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Croissance des infrastructures de santé Base installée et pénétration des nouvelles technologies

Le marché du diagnostic moléculaire vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les équipements en capital, la base installée de différents types de produits pour le marché du diagnostic moléculaire, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché du diagnostic moléculaire. Les données sont disponibles pour la période historique 2011-2021.

Analyse du paysage concurrentiel et des parts de marché du diagnostic moléculaire

Le paysage concurrentiel du marché du diagnostic moléculaire fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du diagnostic moléculaire.

Certains des principaux acteurs opérant sur le marché du diagnostic moléculaire sont :

• F. Hoffmann-La Roche SA (Suisse)
• Hologic, Inc., (États-Unis)
• bioMérieux (France)
• Abbott (États-Unis)
• QIAGEN (Pays-Bas)
• Thermo Fisher Scientific (États-Unis)
• Siemens (Allemagne)
• Danaher (États-Unis)
• Myriad Genetics Inc. (États-Unis)
• Illumina Inc. (États-Unis)
• Agilent Technologies Inc. (États-Unis)
• BD (États-Unis), DiaSorin SpA (Italie)
• Grifols SA (Espagne)
• Quidel Corporation (États-Unis)
• Signatures génétiques (Australie)
• MDxHealth, Inc. (États-Unis)
•  Exact Sciences Corporation (États-Unis)
• Biocartis (Belgique)
• TBG Diagnostics Limited (Australie)
• GenMark Diagnostics Inc. (États-Unis)
• Luminex Corporation (États-Unis)
• HTG Molecular Diagnostics Inc. (États-Unis)
• Vela Diagnostics (Singapour)
• Amoy Diagnostics Co., Ltd. (Chine)
• Molbio Diagnostics Pvt. Ltd. (Inde)
•  geneOmbio (Inde)

SKU-22116